Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. 2012

Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland. julius.popp@chuv.ch

Disturbances of the cholesterol metabolism are associated with Alzheimer's disease (AD) risk and related cerebral pathology. Experimental studies found changing levels of cholesterol and its metabolites 24S-hydroxycholesterol (24S-OHC) and 27-hydroxycholesterol (27-OHC) to contribute to amyloidogenesis by increasing the production of soluble amyloid precursor protein (sAPP). The aim of this study was to evaluate the relationship between the CSF and circulating cholesterol 24S-OHC and 27-OHC, and the sAPP production as measured by CSF concentrations of sAPP forms in humans. The plasma and the CSF concentrations of cholesterol, 24S-OHC and 27-OHC, and the CSF concentrations of sAPPα, sAPPβ, and Aß1-42 were assessed in subjects with AD and controls with normal cognition. In multivariate regression tests including age, gender, albumin ratio, and apolipoprotein E (APOE)ε4 status CSF cholesterol, 24S-OHC, and 27-OHC independently predicted the concentrations of sAPPα and sAPPβ. The associations remained significant when analyses were separately performed in the AD group. Furthermore, plasma 27-OHC concentrations were associated with the CSF sAPP levels. The results suggest that high CSF concentrations of cholesterol, 24S-OHC, and 27-OHC are associated with increased production of both sAPP forms in AD.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006888 Hydroxycholesterols Cholesterol which is substituted by a hydroxy group in any position.
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation

Related Publications

Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
July 2007, Neurobiology of aging,
Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
August 1997, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
January 2020, Archives of gerontology and geriatrics,
Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
June 1993, Neuroreport,
Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
June 2013, Brain research,
Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
January 1990, Journal of molecular neuroscience : MN,
Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
August 2018, European archives of psychiatry and clinical neuroscience,
Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
October 1993, Sheng li ke xue jin zhan [Progress in physiology],
Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
September 2023, International journal of molecular sciences,
Julius Popp, and Piotr Lewczuk, and Heike Kölsch, and Sabrina Meichsner, and Wolfgang Maier, and Johannes Kornhuber, and Frank Jessen, and Dieter Lütjohann
June 1999, The European journal of neuroscience,
Copied contents to your clipboard!